Layout Table~~~~2423~2423~~

Cancer Stem Cells - Emerging Therapeutic, Diagnostic and Market Opportunities~
Published by BioPharm Reports, April 2007

This report provides a comprehensive overview of research on CSCs and the impact this is having on the development of new therapeutic and diagnostic strategies to target cancer. More than 50 academic research teams from 13 different countries have been reviewed, together with leading discoveries in this field. This is driving new research programmes and commercial developments. This report has identified and profiled 17 companies or commercially-focused groups, which now are targeting CSCs, to develop new therapies and diagnostics. The emerging picture on CSCs is creating significant excitement and interest in the cancer field and researchers have proposed a number of drug discovery strategies, which are also reviewed. Many scientists believe that the targeting of CSC’s offers important and revolutionary advances in the targeting of cancer. This report gives the reader a comprehensive and up-to-date overview of developments in this exciting field.~Published by BioPharm Reports, April 2007

Overview
The last decade has seen the emergence of a new paradigm in the therapeutic strategies which may be available to target cancer. This is based on the existence of so called Cancer Stem Cells (CSCs), found in small populations within the bulk of normal proliferating cancer cells, in tumours. Many scientists believe that CSCs are responsible for the development and spread of cancer and explain why the disease is resistant to many conventional treatments and able to reestablish itself after therapy. Many researchers believe the selective targeting of these cells offers revolutionary advances in the treatment of cancer, by attacking the disease at its source. The unique identity of CSCs and their proposed causal role in the development and progression of cancer potentially make these cells an ideal target for the detection of the disease. A number of CSC targeting candidate drugs are now in early research, 2 of which have entered Phase I clinical trials.

Key findings

• Research on CSCs is revealing a unified picture on the involvement of these cells in the development and progression of cancer and this has accelerated discovery programmes to selectively target these cells, alongside normal proliferating cancer cells
• The targeting of CSCs is believed to offer revolutionary advances in cancer therapy and diagnosis
• The CSC field is seeing substantial development, investment and new company formation, as specialised groups advance new discovery programmes
• The targeting of CSCs presents several unique challenges, however a number of strategies have been proposed and are being explored.
• It is believed that diagnostic methods based on the detection of CSC’s will have the potential to address key limitations of current methods
• The first CSC-targeting drug candidates have entered clinical development.

Key Questions answered

• Key research on CSCs and their relevance and impact on drug and diagnostic discovery
• Global research groups working on CSCs (56 identified and reviewed) leading companies and commercial groups focused on CSC’s (17 identified and profiled) and leading developments
• The drug discovery pipeline, candidate molecules, stage of development, drug targets, drug discovery strategies, new discovery opportunities, challenges to drug discovery, the challenges of selectively targeting CSC’s in the laboratory and in the clinic
• Emerging market opportunities and developments including innovation, drug discovery, diagnostics and related areas
• The identification and review of major patents (45) relating to CSCs, from 1999 (publication date) to 2007

Reasons to Order
This report provides a comprehensive overview of research on CSCs and the impact this is having on the development of new therapeutic and diagnostic strategies to target cancer. More than 50 academic research teams from 13 different countries have been reviewed, together with leading discoveries in this field. This is driving new research programmes and commercial developments. This report has identified and profiled 17 companies or commercially-focused groups, which now are targeting CSCs, to develop new therapies and diagnostics. The emerging picture on CSCs is creating significant excitement and interest in the cancer field and researchers have proposed a number of drug discovery strategies, which are also reviewed. Many scientists believe that the targeting of CSC’s offers important and revolutionary advances in the targeting of cancer. This report gives the reader a comprehensive and up-to-date overview of developments in this exciting field.

Table of Contents~Single user license PDF|1012|Two user licenses PDF|1013|Three user licenses PDF|1014|Four user licenses PDF|1015|Five - 99 user licenses|1016|~2423~3141~~

Kinase Screening Profiling Trends 2006~
Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.~Published by HTStec, September 2006

This market report summarizes the results of the second industry-wide global Pharma and Biotech web-based benchmarking survey on kinase screening and profiling. The objective of this study was to document current practices and preferences and to understand future user requirements (particularly in respect of the need for outsourced services) in kinase screening and profiling.

The survey looked at various points including in-house and outsourced kinase screening and profiling as practiced in 2006 and predicted for 2007 and 2008. The following specific areas were investigated : therapeutic areas using kinase assays, kinase panel profiling approach; preferred assay technology, supplier and outsourced fee-for-service providers; kinase profiling budgets and breakdown; interest in label free assays, multiplexed methods of kinase profiling and cell-based approaches for signaling pathway analysis of kinase inhibitors and features of a new kinase platform of greatest interest to respondents.

Table of contents

~Kinase Screening Profiling Trends 2006 (PDF)|749|~2423~2682~~

GPCR Assay Trends~
Published by HTStec, September 2005

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.~
Published by HTStec, September 2005

This market report summarizes the results of a comprehensive global Pharma web-based survey on GPCR assay trends. In particular, it examines through documentation of screening metrics and budgets the relative importance of GPCR primary screening and selectivity profiling both in house and outsourced, the preferences of respondents for assay detection technologies, suppliers/products and fee-for-service providers.

Highlights of this Report:

• The survey collected 63 responses (52 complete and 11 partially filled out) from 48 different Pharma/Biotech companies.
• Responses were split geographically 43% North America and 57% Europe.
• Survey respondents were drawn from 27 Large Pharma, 33 Small Pharma/Biotechs, 1 Large Agro Company, Baby and Clinical Nutrition Company and 1 Pharma-Linked Research Organization.
• Survey respondents represented 27 primary screening (HTS) labs, 15 assay development labs, 12 secondary screening/hits-toleads (lead optimization) labs, 2 therapeutic area labs, 1 compound profiling lab and 6 other lab functions.
• Survey results were expressed as an industry average of all respondents. In addition, all results were fully reanalyzed after subdivision into the following survey groups: 1) by organization type - Large Pharma; 2) by organization type - Small Pharma/Biotech; 3) by geographic location - North America and 4) by geographic location – Europe.
• The mean number of primary GPCR screens undertaken in 2004 was estimated to be 7.1 screens per year with 489K wells (data points) per screen.
• Globally it was estimated that 1533 GPCR primary screens campaigns will be performed in 2004, 71% will be cell-based and 6% orphans.
• The Pharma market for GPCR primary screening reagents was estimated to be US$70Million in 2004, with an annual growth rate of 26%.
• The preferred approaches to GPCR profiling were to either to screen selected lead compounds in house against a GPCR panel or to outsource screening of selected lead compounds to a fee-for-service GPCR panel provider.
• The Pharma market for GPCR profiling was estimated in 2004 to be US$37.6Million and US$36.2Million for in house and outsourced profiling respectively.
• About 8X more data points were profiled against GPCRs in house versus outsourced in 2004.
• The mean budget allocated per lab for GPCR profiling in 2004 was estimated to be US$175K in house versus US$168K for outsourced profiling.
• The mean price per data point for GPCR profiling was estimated to be US$4.30 in house versus US$35.42 for outsourced.
• The mean number of FTEs supporting in house GPCR screening and profiling was 5.4 and 2.8 FTEs/lab respectively.

Table of Contents

~GPCR Assay Trends (PDF)|775|~2423~2621~~

Tissue Microarrays~
Published by Select Biosciences, May 2004

The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.
~Published by Select Biosciences, May 2004

The report provides in-depth information on the market and size segmented by technology and application. In addition to a detailed market model, Tissue Microarrays : Market Assessment and Opportunities evaluates the strengths and weaknesses of each of the TMA vendors, and assesses both opportunities and threats facing their products & services. The companies most likely to dominate specific market segments, as well as the companies most likely to play key supporting roles in moving technologies forward are identified.


View Full Table of Contents~Tissue Microarrays%3A Full Report - Single user print version|48|Tissue Microarrays%3A Full Report - PDF site License +1 print copy|621|~2423~2472~~